Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine   Commentary on Twitter NEW Research—In pts w/ #COVID19 who received IMV for mod-to-sev #ARDS, intravenous immunoglobulins did not improve clinical outcomes at day 28 Phase 3 ICAR trial from Prof Tarek […]

The post RCT: Intravenous immunoglobulins do not improve outcomes in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome. appeared first on Links Medicus.